Javier Alonso-Llamazares

Sep 18, 2024 | jamanetwork.com | Eric Simpson |Lawrence F. Eichenfield |Javier Alonso-Llamazares

Key PointsQuestion  What is the efficacy and safety of once-daily roflumilast cream, 0.15%, in patients with atopic dermatitis (AD)? Findings  In 2 phase 3 randomized clinical trials of 1337 individuals with AD, significantly more patients treated with once-daily roflumilast cream, 0.15%, achieved Validated Investigator Global Assessment for Atopic Dermatitis success at 4 weeks than patients treated with vehicle cream. Roflumilast was well tolerated with low rates of adverse events in both trials.

Mar 13, 2023 | jofskin.org | Andrew Blauvelt |Javier Alonso-Llamazares |Coral Gables |Neal Bhatia

Main Article Content Keywords roflumilast, seborrheic dermatitis, phase 3 trial, tolerability Abstract Introduction: Seborrheic dermatitis (SD) is a common, chronic, inflammatory dermatosis that affects patients of all ages with a global prevalence ≥5%.